Drug intelligence / Profile preview

NKD0901

Development stage: Unknown

Overview

NKD0901 is an investigational drug being evaluated for the treatment of patients with EGFR-positive advanced solid tumors. It is currently under clinical investigation to assess its safety, pharmacokinetics, and anti-tumor activity in this patient population. The precise mechanism of action, molecular target(s), and detailed modality have not been publicly disclosed as of June 2025. The available information indicates that it is a targeted therapy candidate for cancers characterized by EGFR positivity[9].

Other names: NKD0901NKD-0901NKD 0901

Beyond the preview

Go deeper on NKD0901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKD0901.

Explore the full profile